In ALK-rearranged NSCLC, ICIs alone do not appear to be promising; chemotherapy remains the standard after ALK tyrosine kinase inhibitors (TKIs) lose efficacy [10, 78]. This evidence concerns the gene ALK and non-small cell lung carcinoma.